RecruitingPhase 3NCT06441630
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
Sponsor
Addpharma Inc.
Enrollment
251 participants
Start Date
Jul 31, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Signed informed consent
- Patients with Essential Hypertension
- Other inclusions applied
Exclusion Criteria2
- Patient with Secondary Hypertension
- Other exclusions applied
Interventions
DRUGAD-227A
Per Oral, 1 Tablet, Once a day for 8 weeks
DRUGAD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
DRUGAD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
DRUGPlacebo of AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
DRUGPlacebo of AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06441630
Related Trials
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
NCT066438191 location
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
NCT072821451 location
Childhood-Onset Essential Hypertension Natural History Study
NCT067782391 location
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT0705181118 locations
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）
NCT068772341 location